TapewireFind a company

person · Reporting owner

Sukhatme Mayukh

Disclosed activity across 1 company

Tapewire entity
20848
SEC CIK
0001750050

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Roivant Sciences Ltd.ROIV · Entity 3185Director · President & CIOSeptember 30, 2026October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Roivant Sciences Ltd.

Report date September 30, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect18,583,860 Reported balance After 2026-09-30 transaction · row 1
1 source row

Row 1 · 2026-09-30 · Tax withholding · Disposed 46,879 · Balance 18,583,860

F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 30, 2026 Filed Oct 2, 2026 21:38 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 46,879 $36.57 $1,714,365.03
Disclosure

SEC source: 0001635088-26-000109 · wk-form4_1790977119.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,583,860

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
August 21, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 144,756 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · derivative · entry 9

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,224,363

Underlying: Common Shares · 144,756 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 21, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 144,756 $36.48 $5,280,698.88
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 6

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 21, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 144,756 $3.85 $557,310.60
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 5

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,775,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 20, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 17,519 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · derivative · entry 8

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,369,119

Underlying: Common Shares · 17,519 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 20, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 17,519 $37.30 $653,458.70
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 20, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 17,519 $3.85 $67,448.15
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,648,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 19, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 172,899 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · derivative · entry 7

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,386,638

Underlying: Common Shares · 172,899 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 19, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 172,899 $37.17 $6,426,655.83
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 19, 2026 Filed Aug 22, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 172,899 $3.85 $665,661.15
Disclosure

SEC source: 0001140361-26-034066 · form4.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,803,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 18, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares · Derivative 136,942 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · derivative · entry 11

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,559,537

Underlying: Common Shares · 136,942 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 18, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 31,801 $37.18 $1,182,361.18
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 8

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.10 to $37.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 18, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 31,801 $3.85 $122,433.85
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 7

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,662,540

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 18, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 105,141 $36.59 $3,847,109.19
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 6

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $37.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 18, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 105,141 $3.85 $404,792.85
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 5

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,735,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 17, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares · Derivative 284,707 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · derivative · entry 10

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,696,479

Underlying: Common Shares · 284,707 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 17, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 284,707 $36.25 $10,320,628.75
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 17, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 284,707 $3.85 $1,096,121.95
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,915,446

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 14, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares · Derivative 243,177 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · derivative · entry 9

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,981,186

Underlying: Common Shares · 243,177 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
August 14, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 243,177 $36.23 $8,810,302.71
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
August 14, 2026 Filed Aug 19, 2026 01:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 243,177 $3.85 $936,231.45
Disclosure

SEC source: 0001140361-26-033637 · form4.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,873,916

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 30, 2026 Filed Jul 2, 2026 23:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 46,878 $35.39 $1,659,012.42
Disclosure

SEC source: 0001635088-26-000075 · wk-form4_1783033200.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,630,739

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 22:23 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 500,000 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · derivative · entry 6

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,224,363

Underlying: Common Stock · 500,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 22:23 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 500,000 $34.08 $17,040,000.00
Disclosure

SEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,677,617

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
June 26, 2026 Filed Jun 29, 2026 22:23 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 500,000 $3.85 $1,925,000.00
Disclosure

SEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,177,617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 25, 2026 Filed Jun 29, 2026 22:23 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 500,000 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · derivative · entry 5

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,724,363

Underlying: Common Stock · 500,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
June 25, 2026 Filed Jun 29, 2026 22:23 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 500,000 $34.13 $17,065,000.00
Disclosure

SEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,677,617

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
June 25, 2026 Filed Jun 29, 2026 22:23 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 500,000 $3.85 $1,925,000.00
Disclosure

SEC source: 0001635088-26-000073 · wk-form4_1782771783.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,177,617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2026 Filed Apr 1, 2026 23:19 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 187,512 $27.70 $5,194,082.40
Disclosure

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,677,617

F4 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Read SEC document
March 30, 2026 Filed Apr 1, 2026 23:19 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCapped Value Appreciation Rights · Derivative 1,306,889 $11.50 $15,029,223.50
Disclosure

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · derivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 58,391 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.exercise_price: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · shares: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · derivative.exercise_date: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.exercise_date: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F5 · derivative.exercise_date: Award of CVARs is fully vested.

F1 · derivative.underlying_shares: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · derivative.underlying_shares: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

Read SEC document
March 30, 2026 Filed Apr 1, 2026 23:19 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 29,809 $26.41 $787,255.69
Disclosure

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,865,129

F3 · kind: Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs.

Read SEC document
March 30, 2026 Filed Apr 1, 2026 23:19 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 58,391 Not disclosed Not disclosed
Disclosure

SEC source: 0001635088-26-000033 · wk-form4_1775085551.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,894,938

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · kind: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

F1 · price: Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

F2 · price: On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 22:53 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 651,558 $0.00 Strike: $12.68 $0.00
Disclosure

SEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · derivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 651,558 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 22:53 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 312,117 $26.47 $8,261,736.99
Disclosure

SEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,836,547

F3 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 22:53 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 339,441 $26.47 $8,985,003.27
Disclosure

SEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,148,664

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F2 · price: These Common Shares were sold in multiple transactions at prices ranging from $25.92 to $26.78, inclusive.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 22:53 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 651,558 $12.68 $8,261,755.44
Disclosure

SEC source: 0001635088-26-000015 · wk-form4_1770850398.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,488,105

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 31, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 2,449,877 $0.00 Strike: $12.68 $0.00
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · derivative · entry 8

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,718

Underlying: Common Shares · 2,449,877 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
December 31, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,430,882 $21.71 $31,064,448.22
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 6

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,836,547

F4 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
December 31, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 1,018,995 $21.71 $22,122,381.45
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 5

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,267,429

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F3 · price: These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive.

Read SEC document
December 31, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 2,449,877 $12.68 $31,064,440.36
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,286,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 29, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 748,358 $0.00 Strike: $12.68 $0.00
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · derivative · entry 7

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,840

Underlying: Common Shares · 748,358 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
December 29, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 436,485 $21.74 $9,489,183.90
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,836,547

F4 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
December 29, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 311,873 $21.74 $6,780,119.02
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,273,032

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

F2 · price: These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive.

Read SEC document
December 29, 2025 Filed Jan 1, 2026 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 748,358 $12.68 $9,489,179.44
Disclosure

SEC source: 0001140361-25-047122 · form4.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,584,905

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 17, 2025 Filed Dec 20, 2025 02:04 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares · Derivative 59,513 $0.00 Strike: $12.68 $0.00
Disclosure

SEC source: 0001140361-25-046247 · form4.xml · derivative · entry 4

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,304,198

Underlying: Common Shares · 59,513 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares that is fully vested.

Read SEC document
December 17, 2025 Filed Dec 20, 2025 02:04 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 32,682 $23.09 $754,627.38
Disclosure

SEC source: 0001140361-25-046247 · form4.xml · nonDerivative · entry 3

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,836,547

F2 · shares: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
December 17, 2025 Filed Dec 20, 2025 02:04 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 26,831 $23.09 $619,527.79
Disclosure

SEC source: 0001140361-25-046247 · form4.xml · nonDerivative · entry 2

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,869,229

F1 · price: All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document
December 17, 2025 Filed Dec 20, 2025 02:04 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 59,513 $12.68 $754,624.84
Disclosure

SEC source: 0001140361-25-046247 · form4.xml · nonDerivative · entry 1

Sukhatme Mayukh · CIK 0001750050 · Director · President & CIO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,896,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 26, 2024 Filed Dec 27, 2024 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 689,495 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-24-050461 · form4.xml · derivative · entry 9

Sukhatme Mayukh · CIK 0001750050 · Director · Pres&Chief Investment Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,224,363

Underlying: Common Stock · 689,495 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Read SEC document
December 26, 2024 Filed Dec 27, 2024 02:00 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 689,495 $12.01 $8,280,834.95
Disclosure

SEC source: 0001140361-24-050461 · form4.xml · nonDerivative · entry 6

Sukhatme Mayukh · CIK 0001750050 · Director · Pres&Chief Investment Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,836,547

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.